RenovaCare, Inc. RCAR

Company Overview

RenovaCare, Inc. (ticker previously associated with RCAR) is a regenerative medicine and medical device development company focused on technologies intended for the treatment of severe skin injuries, including burns, chronic wounds, and skin defects. The company became known for developing its proprietary SkinGun and CellMist System, which were designed to prepare and apply a suspension of a patient’s own skin cells directly onto wounds to support rapid healing and skin regeneration. RenovaCare operated within the broader biotechnology, regenerative medicine, and medical device industries.

The company’s primary strategic focus centered on autologous cell therapy applications, where patient-derived cells are processed and reapplied without the use of donor tissue. Public disclosures and historical investor materials described the company’s positioning as an alternative to conventional skin grafting procedures, with the potential to reduce scarring and improve recovery outcomes. RenovaCare evolved from an early-stage development enterprise into a publicly traded regenerative medicine company pursuing commercialization and regulatory advancement of its wound-care technologies. However, public information regarding ongoing operations, commercialization progress, and current market activity has become limited in recent years, and some operational details are inconclusive based on available public sources.